Ansa Biotechnologies, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-10-02.
Ansa Biotechnologies, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 2, 2025. The filing reports $46.45M sold. Its industry group is Biotechnology. It names Jason Gammack (Executive Officer, Director), Daniel Lin-Arlow (Executive Officer, Director), Yanniv Dorone (Director) (SEC Form D/A, October 2, 2025).
Is this your company?
Sell to companies like Ansa Biotechnologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ansa Biotechnologies, Inc.
Free to see. No signup.
More on the people and the money behind Ansa Biotechnologies, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in October 2025, largest first.
Get an email when Ansa Biotechnologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ansa Biotechnologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ansa Biotechnologies, Inc. →Get the full cited report on Ansa Biotechnologies, Inc.
What the filing shows about Ansa Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Ansa Biotechnologies, Inc.'s address as 1198 65TH Street #250, Emeryville, CA 94608.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Ansa Biotechnologies, Inc. →
Amended on 2025-12-10: the offering size changed from $55,477,037 to $56,934,922; the amount sold changed from $45,199,665 to $46,449,665; the number of investors changed from 39 to 41. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ansa Biotechnologies, Inc. See pricing
Ansa Biotechnologies, Inc. is a registered filer with the SEC (CIK 1816722) and has filed since 2025-10-02. 2 filings are on record, the latest on 2025-12-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ansa Biotechnologies, Inc.'s Form D of 2025-10-02 names Jason Gammack, Daniel Lin-Arlow, Yanniv Dorone and 3 more as its officers, directors or promoters.
Its new offerings report $45.20M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Jason Gammack is named as Executive Officer and Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
Daniel Lin-Arlow is named as Executive Officer and Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
Yanniv Dorone is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
Matthew McManus is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
Chenny Zhang is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
Sebastian Palluk is named as Executive Officer on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 2 October 2025, one of 6 people that filing names.
6 people named on the filing — 3 holding an executive role and 3 as directors only.
Named as of the 2025-10-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ansa Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ansa Biotechnologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ansa Biotechnologies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Ansa Biotechnologies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Ansa Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/ansa-biotechnologies-inc-form-d-25000001